Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis - Winthrop, K L; Park, S-H; Gul, A; Cardiel, M H; Gomez-Reino, J J; Tanaka, Y; Kwok, K; Lukic, T; Mortensen, E; Ponce de Leon, D; Riese, R; Valdez, H (Annals of the rheumatic diseases, 2016)
Keywords: Antirheumatic Agents - adverse effects; Antirheumatic Agents - therapeutic use; Arthritis, Rheumatoid - drug therapy; Arthritis, Rheumatoid - epidemiology; Arthritis, Rheumatoid - immunology; Clinical and Epidemiological Research; Clinical Trials as Topic; Cytomegalovirus; Herpes viruses; Humans; Immunocompromised Host; Immunosuppressive Agents - adverse effects; Immunosuppressive Agents - therapeutic use; Incidence; Infections; Janus Kinase 3 - antagonists & inhibitors; Kinases; Opportunistic Infections - chemically induced; Opportunistic Infections - epidemiology; Opportunistic Infections - immunology; Patients; Piperidines - adverse effects; Piperidines - therapeutic use; Pneumonia; Protein Kinase Inhibitors - adverse effects; Protein Kinase Inhibitors - therapeutic use; Pyrimidines - adverse effects; Pyrimidines - therapeutic use; Pyrroles - adverse effects; Pyrroles - therapeutic use; Regions; Rheumatoid arthritis; Risk Assessment; Steroids; Tuberculosis; Tuberculosis - chemically induced; Tuberculosis - epidemiology; Tuberculosis - immunology; Tumor necrosis factor-TNF; Viral infections; United States--US; Japan; DMARDs (synthetic); Infections; Treatment; Tuberculosis; Rheumatoid Arthritis